To examine the pattern of sindilizumab's adverse drug reactions (ADRs) and to offer a literature foundation for the medication's sensible therapeutic administration. The databases of the China Knowledge Network (CNKI), Wanfang, Wipu, PubMed, and Web of Science were searched for literature on Sindilizumab. The information on the timing, systems implicated, clinical symptoms, and reversal of adverse reactions was analyzed and summarized after the literature was compiled and its distribution examined.The 53 cases were spread throughout 51 literature papers, the first case report on Sindilizumab ADRs being published in 2020. The patients' ages ranged from 29 to 87, with a mean of 59.90 years. There were 38 men and 15 women among them. In all, 12 cases (22.2%) of the ensuing ADRs involved the endocrine system, which was then followed by the skin, digestive system, and neurological system. Sindilizumab should be monitored and followed up and documented during the course of drug administration, and ADRs should be detected and dealt with in a timely manner to avoid exacerbation.

Zheng Chao, Chen Jie. Literature Analysis of 53 Cases of Sindilizumab-Induced Adverse Drug Reactions. Frontiers in Medical Science Research (2023) Vol. 5, Issue 8: 36-44. https://doi.org/10.25236/FMSR.2023.050805.

[1] S-M Hoy. Sintilimab: First Global Approval [J]. Drugs, 2019, 79(3): 341-346.

[2] Zhou HP, Tang Y, Chen YC, et al. Case analysis and pharmacological monitoring of a case of sindilizumab-induced immune myocarditis with heart failure and respiratory failure[J]. Chinese Pharmacist, 2022, 25(06): 1036-1040.

[3] Shao HX, Hu JW. Pharmacological monitoring of one case of immune-related liver damage adverse reaction caused by sindilizumab injection[J]. Chinese Rural Medicine, 2022, 29(09): 40-41. 

[4] Wu YP, Zhang LN, Yin YS. A case of rare purpura-like cutaneous vasculitis caused by sindilizumab [J]. Chinese Journal of Hospital Pharmacy, 2022, 42(12): 1290-1292.

[5] Xue SHY, Zhang JT, Ji P, et al. One case of hypothyroidism and organ degeneration adverse reactions caused by sindilizumab[J]. Journal of pharmacoepidemiology, 2022, 31(03): 211-213.

[6] Zeng H M, Ding B, Luo L Q. A case of cutaneous immune adverse reaction caused by sindilizumab for advanced esophageal cancer[J]. Oncopharmacology, 2022, 12(01): 132-135.

[7] Fu Z Y, Xie T T. A case of immune-related hyperaldosteronism caused by sindilizumab[J]. China Drug Application and Monitoring, 2022, 19(01): 66-68.

[8] Xu LUJ, Liu CH, Yan MEX, et al. Two case reports of immune-related adverse reactions to sindilizumab and review of the literature[J]. Journal of Clinical Pharmacotherapy, 2022, 20(01): 82-85.

[9] Zhang G M, Song N, Gao M, et al. Pharmacological monitoring of immune-related neurological adverse reactions to sindilizumab[J]. Pharmacopoeia, 2020, 39(12): 1700-1703.

[10] Zhang Wanlu, Ren Wenjing, Xie Zhuolu. A case of sindilizumab-induced phagocytosis syndrome[J]. China Drug Application and Monitoring, 2022, 19(02): 132-134.

[11] Cheng, Y., Li, J., Xiang, L., et al. A case of immune-associated enteritis caused by sindilizumab[J]. Chinese Medical Science, 2022, 12(06): 193-196.

[12] Fu Lixiang, Xiao P, Sun J, et al. Sindilizumab in autoimmune diabetes mellitus[J]. Journal of Adverse Drug Reactions, 2022, 24(02): 101-103.

[13] Shan B, Lv YL, Hou JJ, et al. A case of toxic epidermolysis bullosa caused by sindilizumab[J]. Pharmacopoeia, 2022, 41(02): 263-265.

[14] Liu D W, Fan J T, He X H, et al. A case of severe liver injury caused by sindilizumab for non-small cell lung cancer[J]. Chinese Journal of Oncology, 2021, 43(12): 1325-1326.

[15] Mei D, Ni MX, Gu HJ, et al. Pharmacological practice and analysis of immune-related adverse reactions to sindilizumab[J]. Practical Drugs and Clinics, 2021, 24(12): 1129-1132.

[16] Wang Y, Guo F, Bi LQ, et al. Sindilizumab causes a multisystem immune-related adverse event in a case[J]. Pharmacology and Clinical Research, 2021, 29(06): 462-463.

[17] Zhang Chao, Tao Ying, Hu Jia Li, et al. A case of vitiligo caused by Sindilizumab injection[J]. Chinese Modern Applied Pharmacology, 2021, 38(19): 2431-2432.

[18] Liu D, Gong J, Liao ZK, et al. Report of a case of tuberculosis caused by sindilizumab for non-small cell lung cancer[J]. China Medicine Herald, 2021, 18(23): 189-192.

[19] Gao Yiling, Zhu Minghui, Tang Qiaoyun, et al. Multi-organ toxic reactions to sindilizumab[J]. Journal of Adverse Drug Reactions, 2021, 23(07): 387-389.

[20] Rong Peipei. A case of immune myocarditis caused by thymoma treated with sindilizumab[J]. Anhui Medicine, 2021, 25(06): 1239-1241.

[21] Zhou H P, Chen Y. Pharmacological monitoring practice of a case of immune-associated pancreatitis caused by sindilizumab[J]. Pharmacy Today, 2021, 31(05): 392-39

[22] Liu J, Shi H, Li XH, et al. A case of immune-associated pneumonia caused by sindilizumab and review of the literature[J]. Clinical Medicine Research and Practice, 2021, 6(10): 10-13.

[23] Guo K, Zhu B, Wang F. Analysis of a case of PD-1 inhibitor-induced myositis with myasthenia gravis[J]. Shanghai Medicine, 2020, 41(03): 56-59.

[24] An S-N, Ren W-J, Fu G-Y. Analysis and reflections of clinical pharmacists on adverse reactions to PD-1 antibody agents in two oncology patients[J]. Practical Drugs and Clinics, 2020, 23(07): 637-640.

[25] Yan Qixing, Fang Cao, Pan Yun, et al. A case of herpetic dermatitis caused by advanced lung adenocarcinoma treated with sindilizumab[J]. Chinese Journal of New Drugs and Clinics, 2022, 41(04): 253-256.

[26] Wang CHH, Li QW, Wu W, et al. Sindilizumab causes immune-related hepatitis[J]. Journal of Adverse Drug Reactions, 2020, 22(10): 595-596.

[27] Sun J, Gong Chunyan. Three cases of herpetiform aspergillosis caused by PD-1 inhibitors and literature analysis[J]. Chinese Journal of New Drugs, 2022, 31(05): 509-512.

[28] Lin Mao, Deng Haiyi, Yang Yilin, et al. Report of a case of chest wall tuberculosis after immune checkpoint inhibitor therapy in a patient with non-small cell lung cancer and review of the literature[J]. Chinese Clinical Oncology, 2021, 48(20): 1077-1080.

[29] Wang Cao, Cai J, Wang F, et al. A case of immune-related encephalopathy in a patient with peritoneal metastasis of gastric cancer treated with programmed death protein-1 inhibitor[J]. Chinese Journal of Gastrointestinal Surgery, 2022, 25(03): 266-268.

[30] Wang Y, Luo XH, Yang L, et al. Report of two cases of hyperglycemia after application of programmed death receptor 1 inhibitor and review of the literature[J]. Chinese Journal of Diabetes, 2021, 13(01): 87-90.

[31] Liu YX, Yang YC, Su LQ, et al. A case of multiple endocrine gland abnormalities and hematologic adverse effects induced by programmed death receptor 1 inhibitor for hepatoportal cholangiocarcinoma and review of the literature[J]. Oncology Research and Clinical, 2021, 33(11): 861-863.

[32] Wang YH, Tao He, Li X, et al. A case of lethal toxic epidermal necrolysis relaxation in a patient with advanced squamous cell lung cancer caused by sindilizumab[J]. International Journal of Oncology, 2022, 49(06): 380-382.

[33] Gu YC, Liu Y, Xie C, et al. Three cases of pituitary immune adverse reactions in advanced lung cancer treated with programmed death protein-1 inhibitors[J]. Journal of Peking University (Medical Edition), 2022, 54(02): 369-375.

[34] Xu B, Jia Tongshu, Wu H, et al. A case of immune myositis with myasthenia gravis caused by renal cancer treated with programmed death receptor-1 inhibitor[J]. Henan Medical Research, 2021, 30(30): 5760-5762.

[35] J Yang, Wang Y, Tong X-M. Sintilimab-induced autoimmune diabetes: A case report and review of the literature[J]. World J Clin Cases, 2022, 10(4): 1263-1277.

[36] Q Ai, Chen W, Li Y, et al. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute  Erosive Hemorrhagic Gastritis[J]. Front Immunol, 2022, 13840916.

[37] L Tu, Ye Y, Tang X, et al. Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events[J]. Front Oncol, 2021, 11757069.

[38] Z-X Yang, Chen X, Tang S-Q, et al. Sintilimab-Induced Myocarditis Overlapping Myositis in a Patient With Metastatic  Thymoma: A Case Report[J]. Front Cardiovasc Med, 2021, 8797009.

[39] H Bi, Ren D, Wang Q, et al. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature[J]. Ann Palliat Med, 2021, 10(1): 793-802.

[40] L Wen, Zou X, Chen Y, et al. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression[J]. Front Immunol, 2020, 112076.

[41] M Wang, Xu S, Zhu H. Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review[J]. Front Immunol, 2022, 13823767.

[42] Z Zhong, Wang Z, Li Y, et al. Sintilimab treatment for ureteral carcinoma following bladder cancer leads to leukopenia: a case report[J]. Transl Androl Urol, 2022, 11(2): 277-284.

[43] M Yu, Liu L, Shi P, et al. Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report[J]. Immunotherapy, 2021, 13(15): 1255-1260.

[44] Y Zhao, Cao Y, Wang X, et al. Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report  and Brief Review[J]. Onco Targets Ther, 2022, 15345-351.

[45] X Huang, Yang M, Wang L, et al. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review[J]. Medicine (Baltimore), 2021, 100(19): e25795.

[46] W Yang, Xu X, Xia D, et al. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review[J]. Immunotherapy, 2022, 14(5): 275-282.

[47] S Liang, Yang J, Lin Y, et al. Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment  for a Chordoma Patient: A Case Report and Literature Review[J]. Front Immunol, 2021, 12682262.

[48] Y Chen, Jia Y, Liu Q, et al. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review[J]. Ann Palliat Med, 2021, 10(7): 8512-8517.

[49] Q Xing, Zhang Z-W, Lin Q-H, et al. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma[J]. Ann Transl Med, 2020, 8(5): 250.

[50] C Gao, Xu J, Han C, et al. An esophageal cancer case of cytokine release syndrome with multiple-organ injury induced by an anti-PD-1 drug: a case report[J]. Ann Palliat Med, 2020, 9(4): 2393-2399.

[51] J Hu, Li Y, Chen X, et al. Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab[J]. J Clin Pharm Ther, 2020, 45(6): 1474-1477.

[52] Y-H Li, Zhou Y, Liu Y-Y, et al. Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report[J]. Thorac Cancer, 2021, 12(11): 1780-1783.

[53] National Cancer Institute.Common terminology criteria for adverse events(CTCAE)Version 5.0[S]. U. S. Department Of Health And Human Services, 2017.

[54] Cao YQ, Zhang R, Shi YY, et al. Analysis of adverse reactions to anlotinib reported in the literature [J]. Pharmaceutical Guide, 2022, 41(07): 1052-1055.

[55] Li B, Gao R, Li R, et al. Study on the association of adverse reactions/adverse events in drug clinical trials[J]. Chinese Journal of New Drugs, 2014, 23(12): 1465-1470.

[56] Chinese Physicians Association, Respiratory Physicians Branch, Chinese Physicians Association, Multidisciplinary Oncology Committee. Recommendations for the prevention, treatment and management of toxicity associated with immune checkpoint inhibitors[J]. Chinese Medical Journal, 2022, 102(24): 1811-1832.

[57] Chinese Society of Clinical Oncology Guidelines Working Committee. Chinese Society of Clinical Oncology (CSCO) Guidelines for the Management of Toxicity Associated with Immune Checkpoint Inhibitors 2021 [M]. Beijing: People's Health Publishing House, 2021.

[58] J Ferlay, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018[J]. Eur J Cancer, 2018, 103356-387.

[59] Wang Yanping, Wu Meng, Za Rina, et al. Analysis of the prevalence of malignant tumors among the elderly in Shaanxi Province in 2015[J]. Tumor Prevention and Treatment, 2021, 34(07): 624-629.

[60] Chen Wanqing, Zheng Rongshou, Zhang Siwei, et al. Analysis of malignant tumor incidence and mortality in the elderly population in China in 2013[J]. Chinese Journal of Oncology, 2017, 39(01): 60-66.

[61] S Pilleron, Sarfati D, Janssen-Heijnen M, et al. Global cancer incidence in older adults, 2012 and 2035: A population-based study[J]. Int J Cancer, 2019, 144(1): 49-58.

[62] Chinese Expert Consensus on the Construction of a Multidisciplinary Collaborative Group for the Treatment of Immune Checkpoint Inhibitor-Related Toxicity[J]. Journal of Clinical Oncology, 2022, 27(02): 158-164.

[63] D-J Byun, Wolchok J-D, Rosenberg L-M, et al. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies[J]. Nat Rev Endocrinol, 2017, 13(4): 195-207.

[64] R Barroso-Sousa, Barry W-T, Garrido-Castro A-C, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune  Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis[J]. JAMA Oncol, 2018, 4(2): 173-182.

[65] M Ramos-Casals, Brahmer J-R, Callahan M-K, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38.

[66] Hu X, Cao X, Song YQ, et al. Literature analysis of cephalosporins causing Stevens-Johnson syndrome and toxic epidermolysis bullosa[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(08): 840-845.

[67] J-E Salem, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study[J]. Lancet Oncol, 2018, 19(12): 1579-1589.

[68] J-J Moslehi, Salem J-E, Sosman J-A, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018, 391(10124): 933.